Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sanofi Hopes BioNTech Pact Can Help Reboot Cancer Prospects

This article was originally published in Scrip

Executive Summary

Working hard to re-boot its cancer strategy, Sanofi SA of France has entered its latest multi-year collaboration in the field, this time with German biotech BioNTech AG to discover and develop up to five immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs).


Related Content

Genentech, BioNTech Pact Aims To Make Targeted Cancer Vaccines


Related Companies